S. Shak
Journal of Clinical Oncology · 2001–2023
A researcher in the Science corpus: 9 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Who trusts S. Shak overall
Papers from S. Shak's perspective
Ordered by how strongly the researchers S. Shak trusts endorse each paper. Same corpus, a different order for every researcher.
- Breast cancer classification and prognosis based on gene expression profiles from a population-based study (Proceedings of the National Academy of Sciences of the United States of America)
- Reporting recommendations for tumor marker prognostic studies. (Journal of Clinical Oncology)
- Gene expression profiles of human breast cancer progression (Proceedings of the National Academy of Sciences of the United States of America)
- A multigenic program mediating breast cancer metastasis to bone. (Cancer Cell)
- Expert Commentary. (Histopathology)
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond (Statistics in Medicine)
- Radical Prostatectomy versus Observation for Localized Prostate Cancer (New England Journal of Medicine)
- Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
- The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. (Journal of Urology)
- Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. (Journal of Urology)
Their papers
- Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. (2001) — 945 citations
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer (2023) — 1,046 citations
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) — 692 citations
- A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. (2014) — 718 citations
- Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. (2010) — 713 citations
- Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in a Randomized Trial of Chemotherapy for Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer (2009) — 1,334 citations
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. (2006) — 2,514 citations
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. (2004) — 5,932 citations
- Cardiac dysfunction in the trastuzumab clinical trials experience. (2002) — 1,545 citations